Boston Immune Technologies & Therapeutics

Boston Immune Technologies & Therapeutics is a private, preclinical-to-clinical stage biotech developing a novel class of TNFR superfamily antagonists called TrapMAbs. Its platform technology aims to trap receptor molecules in an inactive state, offering potential efficacy and safety advantages over conventional antibodies for targets previously considered challenging. The company's lead asset, BITR2101 targeting TNFR2 for oncology, is in Phase I, with a second program, BITT311 targeting CD40 for autoimmunity, in IND-enabling studies. BITT operates with a lean team and is positioned in the high-potential but competitive immuno-oncology and autoimmune therapy markets.

Proprietary TrapMAb (Trap Monoclonal Antibody) platform designed to antagonize TNFR superfamily members by trapping nascent receptor molecules in an inactive hexagonal network on the cell surface, offering potential efficacy and selectivity advantages.

BITT competes in the crowded and well-funded fields of immuno-oncology and autoimmune drug development. Major pharmaceutical companies and numerous biotechs are developing antibodies against TNFR2, CD40, OX40, and related targets, though BITT differentiates itself with its unique trapping mechanism. Its success depends on demonstrating superior efficacy or safety profiles.